Efficacy of risedronate administration in osteoporotic postmenopausal women affected by inflammatory bowel disease

Stefano Palomba, Francesco Orio, Francesco Manguso, Angela Falbo, Tiziana Russo, Achille Tolino, Libuse Tauchmanovà, Annamaria Colao, Patrizia Doldo, Pasquale Mastrantonio, Fulvio Zullo

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Patients with inflammatory bowel disease (IBD) have frequently a bone mineral density (BMD) significantly lower than age-matched healthy subjects. The low BMD observed in IBD patients is related also to a higher incidence of bone fractures. In this prospective randomized study we evaluated the effect of 1-year risedronate administration on bone mass and turnover, and on vertebral fractures in osteoporotic postmenopausal women with IBD in remission. Ninety osteoporotic postmenopausal women were randomized to receive oral risedronate 35 mg/week (risedronate group) or placebo tablets (placebo group; one tab/week). The duration of treatment was 12 months. At entry and after treatment, lumbar spine and hip BMD, and serum osteocalcin (OC) and urinary deoxypyridinoline/ creatinine ratio (DPD-Cr) levels were evaluated. Vertebral fractures were assessed from thoracic and lumbar lateral and anterior-posterior spinal radiographs taken at baseline, and from lateral spinal radiographs taken at the end of the study. At study entry, no difference between groups was also detected in BMD and in bone turnover markers. At the end of the study, lumbar spine, trochanter and femoral neck BMD was significantly ( p

Original languageEnglish
Pages (from-to)1141-1149
Number of pages9
JournalOsteoporosis International
Volume16
Issue number9
DOIs
Publication statusPublished - Aug 2005

Fingerprint

Inflammatory Bowel Diseases
Bone Density
Bone Remodeling
Spine
Placebos
Pelvic Bones
Osteoporotic Fractures
Femur Neck
Osteocalcin
Bone Fractures
Femur
Tablets
Creatinine
Healthy Volunteers
Thorax
Risedronate Sodium
Prospective Studies
Incidence
Therapeutics
Serum

Keywords

  • Bisphosphonates
  • Clinical trials
  • Menopause
  • Osteoporosis
  • Risedronate
  • Treatments

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Efficacy of risedronate administration in osteoporotic postmenopausal women affected by inflammatory bowel disease. / Palomba, Stefano; Orio, Francesco; Manguso, Francesco; Falbo, Angela; Russo, Tiziana; Tolino, Achille; Tauchmanovà, Libuse; Colao, Annamaria; Doldo, Patrizia; Mastrantonio, Pasquale; Zullo, Fulvio.

In: Osteoporosis International, Vol. 16, No. 9, 08.2005, p. 1141-1149.

Research output: Contribution to journalArticle

Palomba, S, Orio, F, Manguso, F, Falbo, A, Russo, T, Tolino, A, Tauchmanovà, L, Colao, A, Doldo, P, Mastrantonio, P & Zullo, F 2005, 'Efficacy of risedronate administration in osteoporotic postmenopausal women affected by inflammatory bowel disease', Osteoporosis International, vol. 16, no. 9, pp. 1141-1149. https://doi.org/10.1007/s00198-005-1927-z
Palomba, Stefano ; Orio, Francesco ; Manguso, Francesco ; Falbo, Angela ; Russo, Tiziana ; Tolino, Achille ; Tauchmanovà, Libuse ; Colao, Annamaria ; Doldo, Patrizia ; Mastrantonio, Pasquale ; Zullo, Fulvio. / Efficacy of risedronate administration in osteoporotic postmenopausal women affected by inflammatory bowel disease. In: Osteoporosis International. 2005 ; Vol. 16, No. 9. pp. 1141-1149.
@article{72182f8bd3944d54bed049123d8593b0,
title = "Efficacy of risedronate administration in osteoporotic postmenopausal women affected by inflammatory bowel disease",
abstract = "Patients with inflammatory bowel disease (IBD) have frequently a bone mineral density (BMD) significantly lower than age-matched healthy subjects. The low BMD observed in IBD patients is related also to a higher incidence of bone fractures. In this prospective randomized study we evaluated the effect of 1-year risedronate administration on bone mass and turnover, and on vertebral fractures in osteoporotic postmenopausal women with IBD in remission. Ninety osteoporotic postmenopausal women were randomized to receive oral risedronate 35 mg/week (risedronate group) or placebo tablets (placebo group; one tab/week). The duration of treatment was 12 months. At entry and after treatment, lumbar spine and hip BMD, and serum osteocalcin (OC) and urinary deoxypyridinoline/ creatinine ratio (DPD-Cr) levels were evaluated. Vertebral fractures were assessed from thoracic and lumbar lateral and anterior-posterior spinal radiographs taken at baseline, and from lateral spinal radiographs taken at the end of the study. At study entry, no difference between groups was also detected in BMD and in bone turnover markers. At the end of the study, lumbar spine, trochanter and femoral neck BMD was significantly ( p",
keywords = "Bisphosphonates, Clinical trials, Menopause, Osteoporosis, Risedronate, Treatments",
author = "Stefano Palomba and Francesco Orio and Francesco Manguso and Angela Falbo and Tiziana Russo and Achille Tolino and Libuse Tauchmanov{\`a} and Annamaria Colao and Patrizia Doldo and Pasquale Mastrantonio and Fulvio Zullo",
year = "2005",
month = "8",
doi = "10.1007/s00198-005-1927-z",
language = "English",
volume = "16",
pages = "1141--1149",
journal = "Osteoporosis International",
issn = "0937-941X",
publisher = "Springer London",
number = "9",

}

TY - JOUR

T1 - Efficacy of risedronate administration in osteoporotic postmenopausal women affected by inflammatory bowel disease

AU - Palomba, Stefano

AU - Orio, Francesco

AU - Manguso, Francesco

AU - Falbo, Angela

AU - Russo, Tiziana

AU - Tolino, Achille

AU - Tauchmanovà, Libuse

AU - Colao, Annamaria

AU - Doldo, Patrizia

AU - Mastrantonio, Pasquale

AU - Zullo, Fulvio

PY - 2005/8

Y1 - 2005/8

N2 - Patients with inflammatory bowel disease (IBD) have frequently a bone mineral density (BMD) significantly lower than age-matched healthy subjects. The low BMD observed in IBD patients is related also to a higher incidence of bone fractures. In this prospective randomized study we evaluated the effect of 1-year risedronate administration on bone mass and turnover, and on vertebral fractures in osteoporotic postmenopausal women with IBD in remission. Ninety osteoporotic postmenopausal women were randomized to receive oral risedronate 35 mg/week (risedronate group) or placebo tablets (placebo group; one tab/week). The duration of treatment was 12 months. At entry and after treatment, lumbar spine and hip BMD, and serum osteocalcin (OC) and urinary deoxypyridinoline/ creatinine ratio (DPD-Cr) levels were evaluated. Vertebral fractures were assessed from thoracic and lumbar lateral and anterior-posterior spinal radiographs taken at baseline, and from lateral spinal radiographs taken at the end of the study. At study entry, no difference between groups was also detected in BMD and in bone turnover markers. At the end of the study, lumbar spine, trochanter and femoral neck BMD was significantly ( p

AB - Patients with inflammatory bowel disease (IBD) have frequently a bone mineral density (BMD) significantly lower than age-matched healthy subjects. The low BMD observed in IBD patients is related also to a higher incidence of bone fractures. In this prospective randomized study we evaluated the effect of 1-year risedronate administration on bone mass and turnover, and on vertebral fractures in osteoporotic postmenopausal women with IBD in remission. Ninety osteoporotic postmenopausal women were randomized to receive oral risedronate 35 mg/week (risedronate group) or placebo tablets (placebo group; one tab/week). The duration of treatment was 12 months. At entry and after treatment, lumbar spine and hip BMD, and serum osteocalcin (OC) and urinary deoxypyridinoline/ creatinine ratio (DPD-Cr) levels were evaluated. Vertebral fractures were assessed from thoracic and lumbar lateral and anterior-posterior spinal radiographs taken at baseline, and from lateral spinal radiographs taken at the end of the study. At study entry, no difference between groups was also detected in BMD and in bone turnover markers. At the end of the study, lumbar spine, trochanter and femoral neck BMD was significantly ( p

KW - Bisphosphonates

KW - Clinical trials

KW - Menopause

KW - Osteoporosis

KW - Risedronate

KW - Treatments

UR - http://www.scopus.com/inward/record.url?scp=24044458610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24044458610&partnerID=8YFLogxK

U2 - 10.1007/s00198-005-1927-z

DO - 10.1007/s00198-005-1927-z

M3 - Article

C2 - 15928801

AN - SCOPUS:24044458610

VL - 16

SP - 1141

EP - 1149

JO - Osteoporosis International

JF - Osteoporosis International

SN - 0937-941X

IS - 9

ER -